X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs CADILA HEALTHCARE - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA CADILA HEALTHCARE ASTRAZENECA PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 104.8 32.1 326.5% View Chart
P/BV x 14.9 6.0 250.2% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 ASTRAZENECA PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
CADILA HEALTHCARE
Mar-17
ASTRAZENECA PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,285460 279.3%   
Low Rs634305 207.9%   
Sales per share (Unadj.) Rs189.692.1 205.8%  
Earnings per share (Unadj.) Rs-0.214.8 -1.4%  
Cash flow per share (Unadj.) Rs3.818.5 20.8%  
Dividends per share (Unadj.) Rs03.20 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs68.668.0 101.0%  
Shares outstanding (eoy) m25.001,023.74 2.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.14.2 121.9%   
Avg P/E ratio x-4,712.725.8 -18,254.7%  
P/CF ratio (eoy) x249.620.7 1,205.8%  
Price / Book Value ratio x14.05.6 248.5%  
Dividend payout %021.6 0.0%   
Avg Mkt Cap Rs m23,988391,581 6.1%   
No. of employees `0001.616.9 9.2%   
Total wages/salary Rs m1,60515,002 10.7%   
Avg. sales/employee Rs Th3,040.25,594.5 54.3%   
Avg. wages/employee Rs Th1,029.2890.1 115.6%   
Avg. net profit/employee Rs Th-3.3899.9 -0.4%   
INCOME DATA
Net Sales Rs m4,74094,295 5.0%  
Other income Rs m921,286 7.2%   
Total revenues Rs m4,83295,581 5.1%   
Gross profit Rs m-13019,036 -0.7%  
Depreciation Rs m1013,750 2.7%   
Interest Rs m0450 0.0%   
Profit before tax Rs m-13916,122 -0.9%   
Minority Interest Rs m0338 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m139-3 -4,630.0%   
Tax Rs m51,289 0.4%   
Profit after tax Rs m-515,168 -0.0%  
Gross profit margin %-2.720.2 -13.6%  
Effective tax rate %-3.78.0 -45.8%   
Net profit margin %-0.116.1 -0.7%  
BALANCE SHEET DATA
Current assets Rs m2,72660,223 4.5%   
Current liabilities Rs m2,43553,058 4.6%   
Net working cap to sales %6.17.6 80.9%  
Current ratio x1.11.1 98.6%  
Inventory Days Days7470 105.6%  
Debtors Days Days4188 46.2%  
Net fixed assets Rs m1,03572,984 1.4%   
Share capital Rs m501,024 4.9%   
"Free" reserves Rs m94268,576 1.4%   
Net worth Rs m1,71669,600 2.5%   
Long term debt Rs m024,684 0.0%   
Total assets Rs m4,156152,207 2.7%  
Interest coverage xNM36.8-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.10.6 184.1%   
Return on assets %-0.110.3 -1.2%  
Return on equity %-0.321.8 -1.4%  
Return on capital %017.9 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306NA-   
Fx inflow Rs m37521,280 1.8%   
Fx outflow Rs m47010,874 4.3%   
Net fx Rs m-9610,406 -0.9%   
CASH FLOW
From Operations Rs m-813,495 -0.1%  
From Investments Rs m-146-29,103 0.5%  
From Financial Activity Rs m86223,158 3.7%  
Net Cashflow Rs m7097,556 9.4%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 8.3 3.6%  
FIIs % 15.7 5.9 266.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 11.0 82.7%  
Shareholders   12,856 44,069 29.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  DIVIS LABORATORIES  ALEMBIC LTD  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Energy & PSU Stocks Lose(09:30 am)

Asian stocks are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 1.67% while the Hang Seng is down 0.87%. The Nikkei 225 is trading down by 1.18%.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Feb 22, 2018 10:35 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS